Climb Bio Inc
Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies for immune-mediated diseases. The company develops budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug IV for the treatment of primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus. In addition, the co… Read more
Climb Bio Inc (CLYM) - Total Assets
Latest total assets as of December 2025: $167.74 Million USD
Based on the latest financial reports, Climb Bio Inc (CLYM) holds total assets worth $167.74 Million USD as of December 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Climb Bio Inc - Total Assets Trend (2019–2025)
This chart illustrates how Climb Bio Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Climb Bio Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Climb Bio Inc's total assets of $167.74 Million consist of 63.1% current assets and 36.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 21.3% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2025)
This chart illustrates how Climb Bio Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Climb Bio Inc's current assets represent 63.1% of total assets in 2025, a decrease from 99.5% in 2019.
- Cash Position: Cash and equivalents constituted 21.3% of total assets in 2025, down from 99.2% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Climb Bio Inc Competitors by Total Assets
Key competitors of Climb Bio Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Climb Bio Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Climb Bio Inc generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Climb Bio Inc is currently not profitable relative to its asset base.
Climb Bio Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 15.16 | 31.41 | 12.91 |
| Quick Ratio | 15.16 | 31.41 | 12.91 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $98.86 Million | $ 149.94 Million | $ 48.47 Million |
Climb Bio Inc - Advanced Valuation Insights
This section examines the relationship between Climb Bio Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.16 |
| Latest Market Cap to Assets Ratio | 1.18 |
| Asset Growth Rate (YoY) | -22.8% |
| Total Assets | $167.74 Million |
| Market Capitalization | $198.54 Million USD |
Valuation Analysis
Above Book Valuation: The market values Climb Bio Inc's assets above their book value (1.18 x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Climb Bio Inc's assets decreased by 22.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Climb Bio Inc (2019–2025)
The table below shows the annual total assets of Climb Bio Inc from 2019 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $167.74 Million | -22.77% |
| 2024-12-31 | $217.19 Million | +96.60% |
| 2023-12-31 | $110.47 Million | -18.17% |
| 2022-12-31 | $134.99 Million | -22.08% |
| 2021-12-31 | $173.24 Million | +603.35% |
| 2020-12-31 | $24.63 Million | +15.13% |
| 2019-12-31 | $21.39 Million | -- |